July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–a...

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything ab...

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherap...

The ASCO Post

July 24, 2026

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), i...

The ASCO Post

July 24, 2026

Palliative Care Integrated at Diagnosis Improves QOL for Patients With Breast Cancer in India

Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The...

The ASCO Post

July 24, 2026

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field

The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments fo...

The ASCO Post

July 23, 2026

POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL

According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin signif...

The ASCO Post

July 23, 2026

Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC

Patients with small cell lung cancer (SCLC) and type 1 antineuronal nuclear or “Hu” antibody (ANNA1/Hu-IgG)–related paraneoplastic neurological syndromes may experience longer survival, according to t...

The ASCO Post

July 23, 2026

Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication

Although attitudes toward medical cannabis were generally similar between groups, providers were more likely to report awareness of potential risks; survivors, meanwhile, were more likely than provide...

The ASCO Post

July 22, 2026

Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer

In a cohort study of patients with nonmetastatic colorectal cancer, treatment delays were associated with a higher risk of metastasis, with the magnitude differing by treatment pathway.

The ASCO Post